Biogen Inc (BIIB)

pos +0.00
Today's Range: 0.00 - 0.00 | BIIB Avg Daily Volume: 1,938,300
Last Update: 02/23/17 - 4:00 PM EST
Volume: 0
YTD Performance: 10.06%
Open: $0.00
Previous Close: $284.75
52 Week Range: $223.02 - $333.65
Oustanding Shares: 215,951,945
Market Cap: 62,114,257,940
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 11 11 9
Moderate Buy 1 1 1 1
Hold 4 4 4 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.53 1.53 1.53 1.78
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 16.99
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
16.99 17.00 30.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-1.89% 16.23% -10.08%
Revenue 10.80 0.70 0.18
Net Income 2.90 1.00 0.25
EPS 10.40 1.20 0.29
Earnings for BIIB:
Revenue 10.13B
Average Earnings Estimates
Qtr (03/17) Qtr (06/17) FY (12/17) FY (12/18)
Average Estimate $4.97 $5.14 $20.94 $22.47
Number of Analysts 20 20 19 21
High Estimate $5.28 $5.38 $21.48 $23.83
Low Estimate $4.27 $4.51 $20.28 $19.18
Prior Year $4.79 $5.21 $20.22 $20.94
Growth Rate (Year over Year) 3.77% -1.37% 3.55% 7.30%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Feb 07, 2017 | 7:01 AM EST
BIIB was upgraded to Buy, Citigroup said. $305 price target. See positive risk/reward for the MS product line.
The Fed is simply not a market catalyst this time.
A merger would be smart, profitable ... and attention-grabbing.
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
Drug giants with money to spend and a friendlier regulatory environment should spur deals.
With weak chart patterns and a quantitative downgrade, longs should protect their positions.
Six reasons why the Nasdaq 100 ETF seems ready to pull back.
Microsoft (MSFT) , which makes up about 8.6% of the index. Amazon (AMZN) , which has about a 6.4% weighting. Cisco (CSCO) , which accounts for about 2.7% on QQQ. I've previously written that I'm bearish on Cisco on an intermediate-term basis. Non-Tech QQQ Stocks Look Iffy, Too Some non-tech QQQ components could weigh down the ETF in 2017 as well. These include biotech and health care companies such as Amgen (AMGN) , Biogen (BIIB) , Celgene (CELG) , Express Scripts (ESRX) and others, which all could suffer if Trump tries to limit drug-price increases. Comcast (CMCSA) also represents a relatively large QQQ weighting (about 3%), but the cable giant could suffer from continued "cord cutting" by consumers. Tax Cuts Won't Help QQQ Stocks Trump's plan to lower the effective U.S. corporate tax rate won't materially benefit QQQ components. After all, large tech and health care firms in the Nasdaq 100 already g

Columnist Conversations

The SPDR S&P Biotech ETF (XBI) was trading in a four month symmetrical triangle before it broke out o...
Join me later today as I bring back Toni Hanser to a webinar.  Toni has been away for awhile recovering f...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.